That is the whole point. Cynata uses an IPSC cell lineage that has been carefully screened for genetic mutations. That IPSC cell lineage can then be infinitely expanded and differentiated into MSC cells (no need to continuously source new donors). Cynata owns the global patent for that process.
Whereas with Mesoblasts first generation process, it requires harvesting new cell donations over and over again, because the cells cannot be infinitely expanded. Only IPSC cells have that capability. Yes, MSB can be multiplied in culture to process more doses, but eventually the cells are subject to senescence (i.e gradually lose potency). Harvesting new donors means that each new batch has to be carefully screened for genetic (cancerous) mutations.
If SI showed a significant interest in CYP... what would that spell to the market about MSBs first gen technology? Gotta stick to his guns
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)